Market Closed - Xetra 16:41:26 23/05/2024 BST 5-day change 1st Jan Change
9.185 EUR -4.37% Intraday chart for Evotec SE -10.56% -56.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EVOTEC : Deutsche Bank maintains a Buy rating ZD
Evotec Shares Rise Following Gene Therapy Exit, Q1 Results MT
EVOTEC : RBC gives a Buy rating ZD
Evotec Q1 Net Loss Widens as Revenue Falls MT
Uncertainty at Evotec hampers share price performance DP
EVOTEC : Warburg Research reiterates its Buy rating ZD
EVOTEC : Jefferies keeps its Buy rating ZD
Evotec remains under pressure - 'Too many question marks' DP
EVOTEC : Gets a Buy rating from RBC ZD
Jefferies lowers target for Evotec to 16 Euro - 'Buy' DP
EVOTEC : Jefferies maintains a Buy rating ZD
Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment MT
Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease CI
EVOTEC : Warburg Research reiterates its Buy rating ZD
EVOTEC : RBC reiterates its Buy rating ZD
Bayer: strategic collaboration with Evotec CF
Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies MT
Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases MT
Bayer and Evotec Collaborate to Advance Precision Cardiology CI
EVOTEC : Deutsche Bank gives a Buy rating ZD
The specter of stagflation rears its ugly head again Our Logo
EVOTEC : Buy rating from Deutsche Bank ZD
Top Midday Decliners MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15 DP
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday MT
Chart Evotec SE
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.185 EUR
Average target price
20.79 EUR
Spread / Average Target
+126.35%
Consensus
  1. Stock Market
  2. Equities
  3. EVT Stock
  4. News Evotec SE
  5. Evotec, bioMérieux, Boehringer Form $41 Million JV Focused On Antimicrobial Resistance